剪接介导的 B 细胞恶性肿瘤免疫治疗中的抗原逃逸。
Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies.
机构信息
Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
Blood Cancer Discov. 2022 Mar 1;3(2):87-89. doi: 10.1158/2643-3230.BCD-21-0200.
Abstract
In this issue of Blood Cancer Discovery, Zheng and colleagues identify that alternative RNA splicing of CD22 within B-cell acute lymphoblastic leukemia can result in antigen escape from CD22-targeted immunotherapies. Drug-resistant isoforms of CD22 exist within leukemic cells pretreatment and can influence response to the CD22-directed antibody-drug conjugate inotuzumab ozogamicin, the immunotoxin moxetumomab pasudotox, as well as anti-CD22 chimeric antigen receptor T cells. See related article by Zheng et al., p. 103 (7).
摘要
在本期《Blood Cancer Discovery》中，Zheng 及其同事确定，B 细胞急性淋巴细胞白血病中 CD22 的选择性 RNA 剪接可导致抗原逃避 CD22 靶向免疫疗法。在白血病细胞预处理时存在 CD22 耐药性同工型，可影响对 CD22 导向抗体药物偶联物伊妥珠单抗奥佐米星、免疫毒素莫昔妥莫单抗帕苏妥昔、以及抗 CD22 嵌合抗原受体 T 细胞的反应。详见 Zheng 等人的相关文章，第 103 页（7）。
相似文献
1
Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies.
Blood Cancer Discov. 2022 Mar 1;3(2):87-89. doi: 10.1158/2643-3230.BCD-21-0200.
2
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.
Blood Cancer Discov. 2022 Mar 1;3(2):103-115. doi: 10.1158/2643-3230.BCD-21-0087.
3
Inotuzumab Ozogamicin: First Pediatric Approval.
Paediatr Drugs. 2024 Jul;26(4):459-467. doi: 10.1007/s40272-024-00634-w. Epub 2024 May 23.
4
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Clin Cancer Res. 2021 May 15;27(10):2742-2754. doi: 10.1158/1078-0432.CCR-20-2399. Epub 2021 Feb 18.
5
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
6
Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
J Pediatr Hematol Oncol. 2019 Nov;41(8):e546-e549. doi: 10.1097/MPH.0000000000001440.
7
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
Curr Oncol. 2020 Dec 31;28(1):252-259. doi: 10.3390/curroncol28010027.
8
Loss of CD22 expression and expansion of a CD22 subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.
Ann Hematol. 2021 Nov;100(11):2727-2732. doi: 10.1007/s00277-021-04601-0. Epub 2021 Jul 31.
9
Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Drugs Today (Barc). 2017 Dec;53(12):653-665. doi: 10.1358/dot.2017.53.12.2737934.
10
Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2020 Jul;190(1):e53-e56. doi: 10.1111/bjh.16732. Epub 2020 May 18.
引用本文的文献
1
Global profiling of alternative splicing in non-small cell lung cancer reveals novel histological and population differences.
Oncogene. 2025 Apr;44(14):958-967. doi: 10.1038/s41388-024-03267-y. Epub 2025 Jan 10.
2
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.
Blood. 2023 Nov 16;142(20):1724-1739. doi: 10.1182/blood.2023020400.
3
Targeting alternative splicing in cancer immunotherapy.
Front Cell Dev Biol. 2023 Aug 10;11:1232146. doi: 10.3389/fcell.2023.1232146. eCollection 2023.
4
CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL.
Cancers (Basel). 2023 Mar 4;15(5):1599. doi: 10.3390/cancers15051599.
本文引用的文献
1
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.
Blood Cancer Discov. 2022 Mar 1;3(2):103-115. doi: 10.1158/2643-3230.BCD-21-0087.
2
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5.
3
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.
Nature. 2019 Apr;568(7750):112-116. doi: 10.1038/s41586-019-1054-1. Epub 2019 Mar 27.
4
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1.
5
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.
6
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.
7
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.
8
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.
9
CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16852-7. doi: 10.1073/pnas.1007896107. Epub 2010 Sep 14.
Zotero 插件